Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. (Nasdaq: VIR) files reports and disclosures with the U.S. Securities and Exchange Commission that provide detailed information on its clinical programs, collaborations and financial position. This SEC filings page aggregates those documents and pairs them with AI-generated summaries to help readers understand the key points in each filing.
For Vir Biotechnology, important filings include Form 8-K current reports describing material events, such as the license agreement with Norgine Pharma UK Limited for commercial rights to the tobevibart and elebsiran combination in chronic hepatitis delta across Europe, Australia and New Zealand, and updates on clinical data from the SOLSTICE Phase 2 trial. Other 8-K filings reference quarterly financial results, including cash, cash equivalents and investments, research and development spending, and progress across the ECLIPSE registrational program and oncology pipeline.
Investors following Vir Biotechnology’s infectious disease and oncology strategy can use this page to locate quarterly and annual financial disclosures, business updates reported via 8-K, and other SEC documents that discuss collaborations, licensing arrangements and clinical milestones. AI-powered tools highlight key terms, summarize complex sections and make it easier to identify information related to chronic hepatitis delta development, PRO-XTEN dual-masked T-cell engagers, and the company’s use of platforms such as dAIsY and PRO-XTEN.
The page also provides access to filings that may include details on revenue categories such as collaboration, contract, grant and license revenue, as well as information about material agreements and clinical trial updates referenced in attached press releases. Real-time integration with EDGAR means new Vir Biotechnology filings appear here as they are made public, with concise AI explanations to support faster review and comparison over time.
Vir Biotechnology, Inc. is offering 17,647,059 shares of common stock at a public offering price of $8.50 per share, with an underwriter option to purchase up to 2,647,058 additional shares for 30 days.
The offering is expected to provide net proceeds of approximately $141.1 million (or $162.3 million if the underwriters exercise their option in full), which Vir says it will use to fund its share of global clinical development and potential commercial launch costs for VIR-5500, other TCE programs using the PRO-XTEN® platform, and for working capital and general corporate purposes.
Vir Biotechnology director Vicki L. Sato reported option exercises and related share sales. She exercised a stock option for 42,377 shares of common stock at a price of $1.485 per share and received common shares upon exercise.
On the same date, she sold 42,377 common shares in open-market transactions, including 42,177 shares at a weighted average price of $9.7521 per share and 200 shares at $10.26 per share. The weighted-average sale involved multiple trades between $9.23 and $10.20 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025. After these transactions, she directly owned 1,144,391 Vir Biotechnology common shares.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an automatic sale of 1,430 shares of common stock. The shares were sold at an average price of $9.5326 per share under a Rule 10b5-1 plan to cover tax withholding on vested restricted stock units. After this non-discretionary transaction, he directly holds 69,613 shares.
Vir Biotechnology EVP & CFO Jason O'Byrne reported an automatic sale of 1,634 shares of common stock in an open-market transaction on February 24, 2026 at an average price of $9.5326 per share. According to the disclosure, this was a mandatory sale under a Rule 10b5-1 plan to cover the company’s tax withholding obligations tied to the vesting of restricted stock units, and not a discretionary trade by O'Byrne. After this tax-related sale, he beneficially owned 162,615 shares of Vir Biotechnology common stock.
Vir Biotechnology, Inc. executive vice president and chief medical officer Mark Eisner reported two open-market sales of common stock under a pre-set Rule 10b5-1 trading plan. On February 24, 2026, he sold 1,616 shares at an average price of $9.5326 per share. On February 25, 2026, he sold another 1,889 shares at an average price of $9.82 per share. A footnote states the February 25 sale was an automatic, mandatory sale to cover tax withholding from vested restricted stock units rather than a discretionary trade. After these transactions, Eisner directly owned 154,024 shares of Vir Biotechnology common stock.
Vir Biotechnology, Inc. executive Vanina de Verneuil, EVP, General Counsel and Corporate Secretary, reported two open-market sales of common stock. She sold 13,700 shares on February 25, 2026 at $9.82 per share and 3,117 shares on February 24, 2026 at $9.5326 per share.
The 13,700-share sale was an automatic, mandatory transaction under Rule 10b5-1 to cover tax withholding on vesting restricted stock units and was not a discretionary trade. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2025, and she held 112,982 shares directly after the last reported sale.
Vir Biotechnology, Inc. Chief Executive Officer Marianne De Backer reported an automatic sale of common stock tied to tax withholding. On this transaction date, 14,762 shares of common stock were sold in an open-market transaction at an average price of $9.5326 per share under a Rule 10b5-1 arrangement to satisfy the company’s tax withholding obligations related to vesting restricted stock units, and the filing states the sale was not a discretionary trade by her. After this sale, she held 1,020,704 shares of Vir Biotechnology common stock directly and 53,118 shares indirectly through the Ureel-De Backer Family Trust, where she and her spouse serve as trustees.
SVF Endurance (Cayman) Limited reported multiple open‑market sales of Common Stock of VIR. The filing lists individual transactions between 11/24/2025 and 02/11/2026 with per‑trade share counts and proceeds, including large blocks such as 481,957 shares on 01/23/2026 for $3,652,848.49 and 291,270 shares on 01/22/2026 for $2,146,543.39.
Vanina A. Huard De Verneuil reported proposed sales of Common Stock under a Form 144 filed for Vir Biotechnology. The filing lists recent transfers of 4,445 shares on 02/23/2026 and 3,117 shares on 02/24/2026 with proceeds shown as $33,127.70 and $29,713.11, respectively.
The excerpt also shows restricted stock vesting events: 6,187 shares vested on 02/23/2026 and 7,513 shares vested on 02/24/2026.
Mark D. Eisner reported proposed sales of common stock of VIR under Rule 144. The notice lists a proposed sale through Fidelity Brokerage Services LLC of 1,889 common shares, dated 02/25/2026. The filing also records recent transactions: 2,089 shares sold on 02/23/2026 and 1,616 shares sold on 02/24/2026.